Heska Signs Distribution Agreement with scil animal care company

Release date: 1/29/2015

scil animal care company to Offer Heska Hematology and Chemistry Instruments, Including Heska's New 5 Part Hematology Instrument, Element HT™5

LOVELAND, CO, January 29, 2015 -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a provider of advanced veterinary diagnostic and other specialty veterinary products, announced today a new distribution agreement with the Canadian unit ("scil animal care company Canada") of scil animal care company, a companion animal health distribution company serving Canada, the United States and Europe. scil animal care company Canada will market and promote Heska's full line of hematology, blood gas & electrolytes and chemistry instruments and affiliated consumables, effective immediately.

According to Steve Eyl, Heska's Executive Vice President of Commercial Operations, "Heska is proud to announce an agreement with scil animal care company Canada to provide Heska's leading technology with the broad representation of this organization in Canada. We are excited to further strengthen the close bonds between our world class teams. We are honored that after extensive evaluation, scil has selected Heska as its chemistry, hematology, and blood gas solution for all of Canada's veterinary community. Today, Canada's pet owners and veterinarians now have broad access to the superior results of Heska. It is an exciting development."

About Heska
Heska Corporation (NASDAQ: HSKA - News) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include blood testing instruments and supplies, digital imaging products, software and services, and single use products and services such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.

About scil animal care company
scil animal care company is an international organization with presence in Canada as well as the United States and Europe. Founded in 1998 scil animal care sells as well as provides service and support for laboratory diagnostic and imaging solutions to the veterinarians in the United States, Canada, Germany, France, Italy, the Netherlands and Spain. scil employs over 200 people including more than 70 sales representatives.

scil's diverse product offering includes chemistry analyzers, hematology analyzers, vital signs monitors, digital radiology equipment, laboratory software, Aesculap surgical power tools, Osteosynthesis kits, plates and implants.

On January 19, 2015, Henry Schein, Inc. announced that it has executed a definitive purchase agreement to acquire scil animal care company. This transaction is subject to regulatory approval, and is expected to close in the second quarter of 2015.

Forward-Looking Statements
This announcement contains forward-looking statements regarding Heska's future financial and operating results. These statements are based on current expectations and are subject to a number of risks and uncertainties. Factors that could affect the business and financial results of Heska generally include the following: uncertainties related to Heska's ability to improve its profitability through a distribution relationship; uncertainties related to Heska's ability to compete successfully as compared to Heska's competitors for the time, energy and focus of a given distributor's employees, which will tend to increase sales; risks related to relying on past sales success as an indicator of future success; risks related to relying on estimated market knowledge and perceptions of Heska's products; uncertainties related to the ability of any organization to successfully market, sell and distribute products; risks related to relying on current perceptions of the reputation and quality of personnel or products of any organization; risks related to product development by a third party, including related to product availability and quality; uncertainties related to the initial market penetration and prospects for any new product; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014.

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…